| Literature DB >> 35606543 |
Pascal Bauer1, Lutz Kraushaar2, Oliver Dörr3, Stanislav Keranov3, Holger Nef3, Christian W Hamm3,4, Astrid Most3.
Abstract
SARS-CoV-2 may affect the cardiovascular system and vascular impairment has been reported in healthy young adults recovering from COVID-19. However, the impact of SARS-CoV-2 infection on the vascular function of elite athletes is unknown. We examined 30 healthy male elite athletes (age 25.8 ± 4.6 years) pre-season and at a 6-month follow-up (182 ± 10 days). Vascular function and central blood pressure were calculated using transfer function-based analysis of peripheral arterial waveforms obtained by oscillometry. We performed a two-way repeated-measures ANOVA on the biomarker data, with SARS-CoV-2 status as the between-groups factor and time as the within-groups factor. Subjects who tested positive for SARS-CoV-2 were studied 18 ± 4 days after their positive testing date at follow-up. Of 30 athletes, 15 tested positive for SARS-CoV-2 after the first examination and prior to the follow-up. None had severe COVID-19 or reported any persisting symptoms. The results of the two-way repeated measures ANOVA revealed that there was no significant main effect of COVID-19 on any of the investigated biomarkers. However, there was a significant interaction between the effects of SARS-CoV-2 exposure and time on augmentation index (Aix) (p = 0.006) and augmentation index normalized to a heart rate of 75 beats per minute (Aix@75), (p = 0.0018). The observation of an interaction effect on Aix and Aix@75 in the absence of any main effect indicates a cross-over interaction. Significant vascular alterations in male elite athletes recovering from COVID-19 were observed that suggest vascular impairment. Whether these alterations affect athletic performance should be evaluated in future studies.Entities:
Mesh:
Year: 2022 PMID: 35606543 PMCID: PMC9125957 DOI: 10.1038/s41598-022-12734-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Clinical characteristics of the athletes included at the first examination.
| SARS-CoV-2 positive | Controls | ||||
|---|---|---|---|---|---|
| n = 15 | n = 15 | ||||
| Mean | SD | Mean | SD | ||
| Age (years) | 26 | 4 | 25.6 | 5.3 | 0.847 |
| Height (cm) | 187.1 | 6.9 | 189.9 | 6.3 | 0.254 |
| Weight (kg) | 92.6 | 8.1 | 93.7 | 9.1 | 0.736 |
| Body mass index (kg/m2) | 26.4 | 1.3 | 26 | 2.1 | 0.491 |
| Body surface area (m2) | 2.18 | 0.13 | 2.21 | 0.12 | 0.485 |
| Training history (years) | 9.87 | 4.2 | 10.13 | 5.2 | 0.878 |
| Training per week (h) | 20.1 | 1.6 | 19 | 2.3 | 0.109 |
Results of vascular evaluation showing differences between the baseline (T1) and follow-up examination (T2) in SARS-CoV-2 positive athletes (n = 15) and controls (n = 15).
| SARS-CoV-2 | Controls | p | p | p | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| T1 | T2 | T1 | T2 | ||||||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | COVID | Time | CxT | |
| Brachial systolic BP (mmHg) | 126 | 9.2 | 128 | 5.1 | 126 | 7.1 | 128 | 8 | 0.83 | 0.2 | 0.89 |
| Brachial diastolic BP (mmHg) | 62 | 7.5 | 66.3 | 8.4 | 59 | 8.4 | 64.9 | 7.3 | 0.41 | < | 0.81 |
| Mean brachial BP (mmHg) | 77.6 | 6.5 | 84.3 | 7.1 | 75.3 | 6.1 | 81.7 | 4.7 | 0.15 | < | 0.93 |
| Pulse pressure (mmHg) | 64.1 | 11 | 61.4 | 13.1 | 65.6 | 11.2 | 63.4 | 10.6 | 0.52 | 0.12 | 0.91 |
| Heart rate at rest (bpm) | 54.8 | 8.8 | 59.3 | 8.6 | 62.1 | 12.4 | 60.1 | 11.7 | 0.22 | 0.53 | 0.12 |
| Mean aortic BP (mmHg) | 74.8 | 7.3 | 78.8 | 7.2 | 74.7 | 7.4 | 79.6 | 7.8 | 0.87 | < | 0.77 |
| Central systolic BP (mmHg) | 99 | 6.3 | 101.5 | 4.8 | 98.6 | 5 | 102.5 | 4.7 | 0.88 | 0.42 | |
| Central diastolic BP (mmHg) | 60.8 | 8.9 | 65.4 | 9.2 | 59.2 | 8.4 | 64.8 | 7.2 | 0.68 | < | 0.76 |
| Aortic augmentation pressure (mmHg) | − 6.3 | 3.8 | − 4.6 | 2.9 | − 5.9 | 4.7 | − 4.5 | 4.3 | 0.81 | 0.07 | 0.87 |
| Aortic pulse wave velocity (m/s) | 6 | 0.74 | 6.3 | 0.81 | 6.1 | 1.1 | 6.1 | 0.66 | 0.91 | 0.22 | 0.31 |
| Augmentation index (%) | − 16.1 | 9.4 | − 11.2 | 8.5 | − 15.8 | 10.7 | − 20 | 5.4 | 0.20 | 0.83 | |
| Augmentation index @75 (%) | − 26 | 8.2 | − 20.5 | 8.2 | − 20.5 | 13.3 | − 23.6 | 6 | 0.68 | 0.46 | |
| Total vascular resistance (dyn*s/cm5) | 1436 | 424 | 1404 | 449 | 1288 | 259 | 1275 | 250 | 0.24 | 0.70 | 0.87 |
| Ig-M SARS CoV-2 (S/CO) | 0 | 6.1 | 2.1 | 0 | 0 | < | |||||
| Ig-G SARS CoV-2 (S/CO) | 0 | 4.2 | 2.9 | 0 | 0 | < | |||||
Bold values denote statistical significance at the p< 0.0125 level.
C/T, COVID by time interaction effect; p values are for main effects (COVID and Time respectively) and for interaction effect; BP, Blood pressure; S/CO, Signal/cutoff ratio.
Figure 1Aortic augmentation index @75 bpm at the two time points according to SARS-CoV-2 status and graphical depiction of the two-way repeated measures ANOVA.